| Related Articles |
Utilization and Outcomes of Thrombolytic Therapy for Acute Pulmonary Embolism: A Nationwide Cohort Study.
Chest. 2019 Nov 26;:
Authors: Beyer SE, Shanafelt C, Pinto DS, Weinstein JL, Aronow HD, Weinberg I, Yeh RW, Secemsky EA, Carroll BJ
Abstract
BACKGROUND: There are increased options to deliver thrombolytic treatment for acute, high-risk pulmonary embolism (PE). The goals of this study were to examine practice patterns of systemic thrombolysis and catheter-directed thrombolysis (CDT) and to compare outcomes after CDT with ultrasound facilitation (CDT-US) and CDT alone.
METHODS: We analyzed adults >18 years of age with hospitalizations associated with acute PE and thrombolysis in the 2016 Nationwide Readmissions Database. We identified characteristics associated with the use of systemic thrombolysis and CDT. We then compared CDT-US to CDT alone by evaluating in-hospital events and readmissions. The primary outcomes were in-hospital mortality and 30-day readmission rates.
RESULTS: Among 5,436 hospitalizations, systemic thrombolysis was utilized more often (n=3,376; 62.1%) than CDT (n=2,060; 37.9%). Compared to CDT, systemic thrombolysis was used more frequently in patients with higher rates of vasopressor use (4.3% vs 1.0%), shock (15.8% vs. 6.9%), cardiac arrest (12.7% vs 3.4%), and mechanical ventilation (19.0% vs 5.9%). Among patients who underwent CDT, 417 (20.2%) received CDT-US and 1,643 (79.8%) received CDT alone. Rates of bleeding events, vasopressor use, and mechanical ventilation were similar between therapeutic strategies. After adjustment, in-hospital mortality (OR 1.19, 95% CI 0.63 - 2.26; p=0.59) and 30-day readmission rates (0.75, 0.47 - 1.22; p=0.25) were not significantly different between CDT-US and CDT alone.
CONCLUSIONS: Systemic thrombolysis is utilized more often than CDT in patients with acute PE, in particular among those with a greater prevalence of high-risk features. Among patients treated with CDT, there were no differences in events between CDT-US and CDT alone.
PMID: 31783016 [PubMed - as supplied by publisher]